GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » Additional Paid-In Capital

Keymed Biosciences (HKSE:02162) Additional Paid-In Capital : HK$9,279.3 Mil(As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Keymed Biosciences Additional Paid-In Capital?


Keymed Biosciences's quarterly additional paid-in capital declined from Dec. 2022 (HK$9,475.5 Mil) to Jun. 2023 (HK$9,276.4 Mil) but then increased from Jun. 2023 (HK$9,276.4 Mil) to Dec. 2023 (HK$9,279.3 Mil).

Keymed Biosciences's annual additional paid-in capital increased from Dec. 2021 (HK$0.0 Mil) to Dec. 2022 (HK$9,475.5 Mil) but then declined from Dec. 2022 (HK$9,475.5 Mil) to Dec. 2023 (HK$9,279.3 Mil).

Keymed Biosciences Additional Paid-In Capital Historical Data

The historical data trend for Keymed Biosciences's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keymed Biosciences Additional Paid-In Capital Chart

Keymed Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
- - - 9,475.50 9,279.34

Keymed Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only - - 9,475.50 9,276.42 9,279.34

Keymed Biosciences Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Keymed Biosciences Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Keymed Biosciences's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Keymed Biosciences (HKSE:02162) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » Additional Paid-In Capital
Comparable Companies
HKSE:06826 HKSE:01530 HKSE:06990 HKSE:09969 HKSE:01541 HKSE:09966 HKSE:06660 HKSE:01952 HKSE:02105 HKSE:02315 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
64Z:Germany
Address
No. 18 BioTown Middle Road, Building D2, Tianfu International BioTown, Chengdu, Sichuan, CHN, 610219
Website
https://www.keymedbio.com
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of innovative biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it operates in Hong Kong & Mainland China, out of which the majority is from Mainland China.
Executives
Chen Bo 2201 Interest of corporation controlled by you
Eagle Hero Management Limited 2101 Beneficial owner
Trident Trust Company (hk) Limited 2301 Trustee
Moonshot Holdings Limited 2101 Beneficial owner
Hh Kny Holdings Limited
Hillhouse Investment Management, Ltd.
Boyu Capital Group Holdings Ltd
Xyxy Holdings Ltd.
Tong Xiaomeng

Keymed Biosciences (HKSE:02162) Headlines

No Headlines